Post-Test HER2-Positive Metastatic Breast Cancer: Where are We Headed? Post-Test Which of the following is true regarding HER2-positive breast cancer? HER2 is overexpressed in approximately 30% of patients HER2 is overexpressed in approximately 50% of patients HER2-positive breast cancer patients are unlikely to develop brain metastases Nearly 50% of HER2-positive breast cancer patients will develop brain metastases Tucatinib is FDA-approved in combination with which of the following therapies based on the HER2CLIMB trial? Capecitabine and trastuzumab Margetuximab and trastuzumab Pertuzumab and trastuzumab Tucatinib and trastuzumab Approximately what percentage of patients developed interstitial lung disease or pneumonitis with trastuzumab deruxtecan treatment in the DESTINY-03 trial and subsequent long-term data analyses? 5% 15% 20% 30% Please rate your ability to treat patients with HER2-low and HER2-positive breast cancer patients. Excellent Very Good Good Fair Poor Previous
